Compare ANIX & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | LFVN |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 78.0M |
| IPO Year | 2013 | 1996 |
| Metric | ANIX | LFVN |
|---|---|---|
| Price | $2.75 | $6.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.67 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 332.0K | 46.2K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $210,000.00 | ★ $203,204,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.50 |
| Revenue Growth | N/A | ★ 1.86 |
| 52 Week Low | $2.32 | $3.90 |
| 52 Week High | $5.46 | $11.71 |
| Indicator | ANIX | LFVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 51.74 |
| Support Level | $2.73 | $6.26 |
| Resistance Level | $3.09 | $6.78 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 16.36 | 55.84 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.